Kinetics of plasma microRNA-499 expression in acute myocardial infarction

Xi Chen1*, Lizhu Zhang1*, Tong Su1, Heng Li1, Qiang Huang1, Dan Wu1, Chengjian Yang1, Zhijun Han2

1Department of Cardiology, 2Department of Laboratory Medicine, Wuxi Second People’s Hospital of Nanjing Medical University, Wuxi 214002, China *These authors contributed equally to this work.

Correspondence to: Chengjian Yang. Department of Cardiology, Wuxi Second People’s Hospital of Nanjing Medical University, Wuxi 214002, China. Email: doctory2071@sina.com; Zhijun Han. Department of Laboratory Medicine, Wuxi Second People’s Hospital of Nanjing Medical University, Wuxi 214002, China. Email: zjhan1125@163.com.

Background: MicroRNA (miRNA) is reported to be present in human plasma and has been increasingly suggested as a biomarker for diseases. Our study aimed to investigate the kinetics of cardiac-specific microR-499 (miR-499) in acute myocardial infarction (AMI).

Methods: Circulating concentrations of cardiac enriched miR-499 were measured by quantitative PCR in 73 patients with acute coronary syndrome (ACS), including 53 with AMI and 20 with unstable angina (UA). Thirty healthy subjects were used as controls. Plasma samples in AMI group were obtained immediately after admission and at 12 h, 24 h, 3 d and 7 d after onset of symptoms. Plasma samples in UA and healthy control groups were collected immediately after admission. The severity and extent of coronary stenotic lesions were evaluated on the basis of coronary angiography using Gensini score.

Results: miR-499 expression levels were significantly higher in the 53 AMI patients than in the 20 UA patients and 30 healthy controls immediately after admission (P<0.01). A measurable increase in miR-499 levels was observed in AMI patients within 24 h of the last onset of chest pain and the levels returned to the baseline after 7 d. Plasma miR-499 levels in the patients with AMI were positively-correlated with cTnI (r=0.384, P<0.01) and CK-MB (r=0.402, P<0.01). In addition, miR-499 levels in AMI patients with two- and three-vessel coronary artery disease (CAD) were significantly higher than those in patients with single-vessel CAD (P<0.05). Gensini scores were used to evaluate the severity of coronary stenosis. miR-499 were positively correlated with Gensini scores (r=0.52, P<0.01). miR-499 levels at admission were significantly higher than that those 24 h after percutaneous coronary intervention (PCI) in AMI patients (P<0.01) and were negatively correlated with LVEF (r=0.36, P=0.008).

Conclusions: Cardiac-specific miRNA-499 levels were found to be linearly proportional to myocardial damage. MiRNA-499 might prove to be a new biomarker for AMI and a predictor of the risk of myocardial ischemia.

Keywords: MicroRNA (miRNA); acute myocardial infarction (AMI); biomarker

Submitted Jul 15, 2014. Accepted for publication Oct 09, 2014.
doi: 10.3978/j.issn.2072-1439.2014.11.32
View this article at: http://dx.doi.org/10.3978/j.issn.2072-1439.2014.11.32

Introduction

Acute myocardial infarction (AMI) is the one of the leading causes of morbidity and mortality worldwide. At present, the diagnosis of AMI mainly depends on clinical symptoms, electrocardiographic (ECG) changes and circulating biomarkers. As clinical presentations and echocardiographic findings are often nonspecific in patients with chest pain, cardiac biomarkers are more important for the diagnosis of AMI. Current biomarkers including CK-MB and troponins have been widely applied to the clinical diagnosis of AMI, but they have several shortcomings such as slow-
release patterns or limitations in specificity (1-3). It is therefore necessary to seek new more sensitive and specific biomarkers of AMI.

MicroRNA (miRNA) is a type of small molecular non-coding RNA with the length about 21-25 nucleotides (4). Accumulating evidence has indicated that miRNAs play a key role in various diseases such as leukemia, progressive liver disease, and neurodegenerative diseases (5-7). In addition, miRNAs were shown to be very stable in circulating blood (8), and the levels of individual miRNA and specific miRNA signatures were reported to be associated with the diagnosis and prognosis of cardiovascular diseases (9). Some recent studies (10,11) have demonstrated that miRNAs, including miR-1, miR-133a and miR-208a, are cardio- or skeletal- muscle specific, and therefore have been proposed as candidate biomarkers for myocardial infarction.

Our prophase study showed that microR-499 (miR-499) released into the circulation during AMI and could be used to detect and monitor the myocardial injury (12). Most studies have focused on the acute phase of myocardial infarction. The present study intended to detect miR-499 levels in AMI patients, and see whether miR-499 is associated with the severity and extent of coronary stenotic lesions and observe changes in plasma miR-499 during emergency percutaneous coronary intervention (PCI).

Materials and methods

Study population

In this study, 73 patients with acute coronary syndrome (ACS), including 53 patients with AMI and 20 patients with unstable angina (UA), who were admitted to emergency and cardiology departments in Wuxi Second People’s Hospital (Wuxi, China) between January 2013 and December 2013. All of these patients were consecutively included from the admitted patients. The inclusion criteria for patients with AMI were based on the newly developed universal definition of MI (13). Briefly, patients with AMI were clinically diagnosed by biochemical markers (cTnI >0.1 ng/mL), acute ischemic-type chest pain, ECG changes, and coronary angiography. The diagnostic criteria for UA were as follows: chest pain with an accelerating pattern or a prolonged duration (>20 min) or recurrent episodes at rest or with minimal effort and ischemic ECG changes such as ST-segment elevation, ST-segment depression of 0.1 mV, or T-wave inversion in at least two contiguous ECG leads.

In addition, 30 healthy adult volunteers who underwent routine physical examinations in our hospital were enrolled as the control. Patient characteristics and clinical features are described in Table 1.

The research protocol was recognized by the Ethics Committee in Wuxi Second People’s Hospital. Informed consent was obtained from all subjects before initiation of the study.

Plasma collection and storage

Plasma samples in AMI group were obtained immediately after admission and at 12 h, 24 h, 72 h and 7 d after onset of the symptoms. The duration between the onset chest pain and arrival at the emergency room was 4.46±3.36 h. Blood samples in UA group were collected immediately after admission. All plasma samples (3-5 mL) were extracted from citrated tubes and stored at −80 °C.

Coronary angiography and diagnostic criteria for coronary artery disease (CAD)

All coronary angiograms were performed by experienced investigators who were blinded to the study, using transradial or transfemoral approaches. At least four projections of the left anterior descending artery and the circumflex artery and two projections of the right coronary artery were taken into consideration. CAD was defined as the presence of one or more coronary stenoses with lumen narrowing more than 50% in a given patient. The extent of CAD was coded as 0, 1, 2, or 3 or more depending on the number of major coronary vessels with luminal stenosis more than 50%. Left main coronary artery stenosis 50% was considered as a two vessel disease.

Gensini score

Gensini score (14) was used to assess the severity of coronary artery stenosis. When the severity of coronary artery stenosis was 0-25%, 26-50%, 51-75%, 76-90%, 91-99% and 100%, the score was 1, 2, 4, 8, 16 and 32 points, respectively. The coefficient was determined in accordance with the locations of coronary artery lesions: 5 points for the left trunk; 2.5, 1.5 and 1 point for the proximal segment, middle segment and distal segment of the left anterior descending branch respectively; 2.5 and 1 point for the proximal segment and distal segment of the circumflex branch respectively; 1 point for the right coronary artery,
the first diagonal branch, the second diagonal branch and the posterior branch of the left ventricle; and 0.5 point for the others.

**Detection of miR-499**

Total RNA was extracted from the plasma samples using the mirVana PARIS kit (Ambion, Applied Biosystem) with enrichment for small RNAs. Reverse transcription of miRNA was performed with the miScript reverse transcription kit (Applied Biosystem). miR-499 was quantitated by using TaqMan miRNA quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) assay according to the protocol of the manufacturer (Applied BioSystems). U6RNA was performed as a miRNA internal control.

The data were analyzed with automatic setting for assigning baseline; the threshold cycle (Ct) was defined as the fractional cycle number at which the fluorescence exceeds the given threshold. The Ct values from real-time PCR assays greater than 40 were treated as 40. The plasma levels of miRNA were detected and analyzed by two investigators who were blinded to the clinical data of the patients. Expression values were normalized by using the mean Ct, and the data obtained by real-time PCR were translated in log2 (relative level) (15,16).

**Statistical analyses**

Experimental data are expressed as the mean ± standard deviation (±SD). Before the analyses, all data were subjected to a normality test (Shapiro-Wilk). The Kruskal-Wallis H test or one-way ANOVA were used to compare data between the three groups, and the LSD t-test was used for inter-group comparisons. To assess whether the time courses of miR-499 expression differed, we compared them by repeated measures ANOVA. Correlations between two variables were determined by the Spearman tests. Statistical analyses were performed with the SPSS statistical package. Statistical analyses were performed with the SPSS statistical package. P values <0.05 were considered statistically significant.

---

**Table 1** Demographic and clinical characteristics of the patients and healthy control

<table>
<thead>
<tr>
<th>Group</th>
<th>AMI</th>
<th>UA</th>
<th>Control</th>
<th>P (AMI vs. UA vs. control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population</td>
<td>53</td>
<td>20</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
<td>68.8±7.3</td>
<td>66.2±5.1</td>
<td>70.3±7.9</td>
<td>0.131</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>44/9</td>
<td>15/5</td>
<td>24/6</td>
<td>0.739</td>
</tr>
<tr>
<td>Hypertension (n, %)</td>
<td>37 (69.8)</td>
<td>13 (65.0)</td>
<td>15 (50.0)</td>
<td>0.195</td>
</tr>
<tr>
<td>Diabetes (n, %)</td>
<td>12 (22.6)</td>
<td>9 (45.0)</td>
<td>7 (23.0)</td>
<td>0.136</td>
</tr>
<tr>
<td>Tobacco (n, %)</td>
<td>33 (62.3)</td>
<td>12 (60.0)</td>
<td>15 (50.0)</td>
<td>0.544</td>
</tr>
<tr>
<td>TC (mmol/L)</td>
<td>4.16±0.94</td>
<td>3.85±1.13</td>
<td>3.78±0.83</td>
<td>0.153</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.76±0.92</td>
<td>1.63±1.01</td>
<td>1.37±0.67</td>
<td>0.149</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>1.12±1.28</td>
<td>1.13±0.37</td>
<td>1.23±0.36</td>
<td>0.290</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>2.69±0.91</td>
<td>2.35±0.94</td>
<td>2.32±0.71</td>
<td>0.119</td>
</tr>
<tr>
<td>Cr (μmol/L)</td>
<td>70.7±13.7</td>
<td>69.9±12.2</td>
<td>68.1±11.0</td>
<td>0.661</td>
</tr>
<tr>
<td>Medications, n [%]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-blockers</td>
<td>20 [38]</td>
<td>6 [30]</td>
<td>–</td>
<td>0.595</td>
</tr>
<tr>
<td>CCB</td>
<td>10 [17]</td>
<td>3 [15]</td>
<td>–</td>
<td>0.751</td>
</tr>
<tr>
<td>ACEI</td>
<td>16 [31]</td>
<td>2 [10]</td>
<td>–</td>
<td>0.710</td>
</tr>
<tr>
<td>ARB</td>
<td>14 [26]</td>
<td>6 [30]</td>
<td>–</td>
<td>0.775</td>
</tr>
<tr>
<td>Nitrates</td>
<td>21 [40]</td>
<td>11 [55]</td>
<td>–</td>
<td>0.294</td>
</tr>
<tr>
<td>Statins</td>
<td>48 [91]</td>
<td>15 [75]</td>
<td>–</td>
<td>0.124</td>
</tr>
</tbody>
</table>

All AMI patients with a large thrombus burden received aspirin, clopidogrel, heparin and abciximab. TC, total cholesterol; TG, total glyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Cr, creatinine; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin inhibitors.
Results

The pattern of plasma miR-499 levels in acute myocardial infarction (AMI)

This study included 53 AMI patients, 20 UA patients, and 30 healthy controls. The baseline clinical characteristics of the groups are shown in Table 1. There were no significant differences in the clinical characteristics of the patients between the three groups. Blood samples were obtained from each AMI patient at various time points (T0 h, 12 h, 24 h, 72 h, and 7 d) after the onset of AMI. The first plasma sample was obtained immediately after admission (T0 h). The average duration between the onset of chest pain and arrival at the emergency room was 4.46±3.36 h. As shown in Figure 1A, plasma samples in AMI, UA and healthy groups were drawn immediately after admission, the relative level of plasma miR-499 in 53 patients with AMI (5.12±2.29) was significantly higher than that in UA group (2.75±1.39) and healthy control group (0.50±0.35), and the differences were statistically significant (P<0.01). We also investigate the time course of plasma miR-499 levels in AMI patients (Figure 1B). The relative level of plasma miR-499 was 5.40±2.24, 3.47±2.43, 2.11±2.88 and 0.77±2.86 at 12 h, 24 h, 72 h and 7 d after onset of symptoms respectively, and returned to the baseline level after 7 d, when it was not significantly different from that in healthy control group (P>0.05). Furthermore, correlation analysis showed a positive correlation between circulating levels of miR-499 and cTnI concentrations in AMI patients (Figure 1C, r=0.384, P<0.01), as well as between miR-499 and CK-MB (Figure 1D, r=0.402, P<0.01). These data suggested that circulating miR-499 might be regarded as a novel biomarker of AMI.

MicroRNA (miRNA)-499 and the severity of coronary atherosclerosis

Of the 53 AMI patients, 42 patients underwent coronary angiography, who were divided into three subgroups according to the number of affected branches (n=1, 2 and 3). The relative level of miR-499 was 3.82±1.98, 5.53±2.62 and 5.92±1.97, respectively. It was higher in two- and three-vessel CAD than that in single-vessel CAD (P<0.05) (Figure 2A). The Gensini scoring system was used to evaluate the
severity and extent of coronary stenotic lesions in the 42 AMI patients by coronary angiography. Spearman's correlation analysis showed that plasma miR-499 levels were positively correlated with the severity of coronary stenosis ($r=0.52$, $P<0.01$) (Figure 2B).

**miRNA-499 expression in AMI patients after emergency PCI**

Of the 53 AMI patients, 29 patients received emergency PCI successfully. As shown in Figure 2C, circulating miR-499 level at 24 h after PCI was significantly lower than that at admission in the emergency PCI group ($P<0.01$); plasma miR-499 levels at 24 h after PCI was significantly lower than those in the non-PCI group ($P<0.01$). AMI, acute myocardial infarction; UA, unstable angina.

**Correlation between miRNA-499 and myocardial systolic function**

We investigated whether circulating cardiac-specific miRNA-499 levels correlated with long-term myocardial systolic function, as measured by LVEF. As shown in Figure 3, we found that miRNA-499 levels were negatively correlated with LVEF ($r=−0.36$, $P=0.008$). Scatter plots for these dates are shown in additional file 1: Figure 3.
Discussion

Recent studies (16-18) have shown that miR-499 may be a clinically practicable biomarker for AMI. Adachi et al. (17) proposed that miR-499 level was increased significantly at 6 and 12 h after myocardial infarction. Devaux et al. (16) found that miR-499 level was elevated significantly in AMI patients within 3 h after chest pain and was positively correlated with hs-cTnT, the positive rate of miR-499 being 93%. Olivieri et al. (18) found that plasma miR-499-5p in elderly NSTEMI patients was nearly 80-fold that in healthy control group, and its sensitivity and specificity were significantly higher than hs-TnT. However, these studies mostly focused on the acute phase of myocardial infarction. An ideal biomarker should not only have sensitivity and specificity but be measureable with respect to myocardial damage (19). Our study aimed to investigate the kinetics of plasma cardiac-specific miR-499 in AMI and see whether it is associated with the severity and extent of coronary stenotic lesions.

In our study, we found that plasma miR-499 levels significantly increased in the AMI group within 12 h after the onset of symptoms, and eventually returned to baseline levels, which were not significantly different from those in the healthy control group, and its sensitivity and specificity were significantly higher than hs-TnT. However, these studies mostly focused on the acute phase of myocardial infarction. An ideal biomarker should not only have sensitivity and specificity but be measureable with respect to myocardial damage (19). Our study aimed to investigate the kinetics of plasma cardiac-specific miR-499 in AMI and see whether it is associated with the severity and extent of coronary stenotic lesions.

In our study, we found that plasma miR-499 levels significantly increased in the AMI group within 12 h after the onset of symptoms, and eventually returned to baseline levels, which were not significantly different from those in the healthy control group, and its sensitivity and specificity were significantly higher than hs-TnT. However, these studies mostly focused on the acute phase of myocardial infarction. An ideal biomarker should not only have sensitivity and specificity but be measureable with respect to myocardial damage (19). Our study aimed to investigate the kinetics of plasma cardiac-specific miR-499 in AMI and see whether it is associated with the severity and extent of coronary stenotic lesions.

In our study, we found that plasma miR-499 levels significantly increased in the AMI group within 12 h after the onset of symptoms, and eventually returned to baseline levels, which were not significantly different from those in the healthy control group, and its sensitivity and specificity were significantly higher than hs-TnT. However, these studies mostly focused on the acute phase of myocardial infarction. An ideal biomarker should not only have sensitivity and specificity but be measureable with respect to myocardial damage (19). Our study aimed to investigate the kinetics of plasma cardiac-specific miR-499 in AMI and see whether it is associated with the severity and extent of coronary stenotic lesions.

In our study, we found that plasma miR-499 levels significantly increased in the AMI group within 12 h after the onset of symptoms, and eventually returned to baseline levels, which were not significantly different from those in the healthy control group, and its sensitivity and specificity were significantly higher than hs-TnT. However, these studies mostly focused on the acute phase of myocardial infarction. An ideal biomarker should not only have sensitivity and specificity but be measureable with respect to myocardial damage (19). Our study aimed to investigate the kinetics of plasma cardiac-specific miR-499 in AMI and see whether it is associated with the severity and extent of coronary stenotic lesions.

In conclusion, miR-499 may prove to be a new biomarker for the diagnosis of AMI and clinical evaluation of the risk of myocardial ischemia, thus improving the sensitivity and specificity of screening patients with myocardial infarction and evaluation of effective reperfusion for myocardial ischemia.
References


